JP2011511003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511003A5 JP2011511003A5 JP2010545233A JP2010545233A JP2011511003A5 JP 2011511003 A5 JP2011511003 A5 JP 2011511003A5 JP 2010545233 A JP2010545233 A JP 2010545233A JP 2010545233 A JP2010545233 A JP 2010545233A JP 2011511003 A5 JP2011511003 A5 JP 2011511003A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- dihydropyrido
- fluoro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, carbonylamino, aminocarbonyl Chemical group 0.000 claims 90
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000005842 heteroatom Chemical group 0.000 claims 16
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 claims 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 150000002923 oximes Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- DRQRNJQGXVDZBU-TZIWHRDSSA-N (2r)-2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-4-hydroxy-n,n-dimethylbutanamide Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\O[C@H](CCO)C(=O)N(C)C)=N1 DRQRNJQGXVDZBU-TZIWHRDSSA-N 0.000 claims 1
- DRQRNJQGXVDZBU-CTNGQTDRSA-N (2s)-2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-4-hydroxy-n,n-dimethylbutanamide Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\O[C@@H](CCO)C(=O)N(C)C)=N1 DRQRNJQGXVDZBU-CTNGQTDRSA-N 0.000 claims 1
- VWBPRIBQAARILO-MJGOQNOKSA-N (2s)-4-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-2-hydroxybutanamide Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC[C@H](O)C(N)=O)=N1 VWBPRIBQAARILO-MJGOQNOKSA-N 0.000 claims 1
- NELKHPYWKAUWEN-MJGOQNOKSA-N (2s)-4-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-2-hydroxybutanoic acid Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC[C@H](O)C(O)=O)=N1 NELKHPYWKAUWEN-MJGOQNOKSA-N 0.000 claims 1
- WZUYUECAUGEKFC-SQJMNOBHSA-N (4s)-4-[[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxymethyl]-3-benzyl-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OC[C@H]2N(C(=O)OC2)CC=2C=CC=CC=2)=N1 WZUYUECAUGEKFC-SQJMNOBHSA-N 0.000 claims 1
- NOELJGWWOVBLOL-KBXCAEBGSA-N (5s)-5-[[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxymethyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OC[C@H]2OC(=O)NC2)=N1 NOELJGWWOVBLOL-KBXCAEBGSA-N 0.000 claims 1
- LVDVFHGRIJTUMH-OAQYLSRUSA-N (7r)-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-5-n-(2-morpholin-4-ylethoxy)-7,8-dihydropyrido[4,3-d]pyrimidine-2,5-diamine Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCCN2CCOCC2)=N1 LVDVFHGRIJTUMH-OAQYLSRUSA-N 0.000 claims 1
- VPUBOTVYSMAHIN-OTOKDRCRSA-N (7r)-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-5-n-(morpholin-2-ylmethoxy)-7,8-dihydropyrido[4,3-d]pyrimidine-2,5-diamine Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC2OCCNC2)=N1 VPUBOTVYSMAHIN-OTOKDRCRSA-N 0.000 claims 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- HDFHEIOIKDQXSX-LMNIDFBRSA-N 2-[2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxyacetyl]-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-6-one Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC(=O)N2CC3N(C(CC3)=O)CC2)=N1 HDFHEIOIKDQXSX-LMNIDFBRSA-N 0.000 claims 1
- YJOHWPAQHRFQFA-GOSISDBHSA-N 2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-1-(3,3-difluoroazetidin-1-yl)ethanone Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC(=O)N2CC(F)(F)C2)=N1 YJOHWPAQHRFQFA-GOSISDBHSA-N 0.000 claims 1
- NQHCNSDEHKYAOC-OAQYLSRUSA-N 2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-1-(4-hydroxypiperidin-1-yl)ethanone Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC(=O)N2CCC(O)CC2)=N1 NQHCNSDEHKYAOC-OAQYLSRUSA-N 0.000 claims 1
- NXWODOMWROKIKJ-DUSLRRAJSA-N 2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-4-hydroxybutanamide Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OC(CCO)C(N)=O)=N1 NXWODOMWROKIKJ-DUSLRRAJSA-N 0.000 claims 1
- VCEAAVLZGHPLBA-HXUWFJFHSA-N 2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxy-n-(2-methoxyethyl)-n-methylacetamide Chemical compound C1([C@@H]2N\C(C3=C(C)N=C(N)N=C3C2)=N/OCC(=O)N(C)CCOC)=CC=C(F)C=C1C1=CC=CC(OC)=N1 VCEAAVLZGHPLBA-HXUWFJFHSA-N 0.000 claims 1
- VXBCMBJFQXGFJD-GOSISDBHSA-N 2-[[2-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxyacetyl]-methylamino]acetamide Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC(=O)N(C)CC(N)=O)=N1 VXBCMBJFQXGFJD-GOSISDBHSA-N 0.000 claims 1
- ZPNUCOCBFHMOMV-GOSISDBHSA-N 3-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxypropan-1-ol Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCCCO)=N1 ZPNUCOCBFHMOMV-GOSISDBHSA-N 0.000 claims 1
- YJQOTPHRPJQSLQ-FQNRMIAFSA-N 4-[[(7r)-2-amino-7-[2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxybutane-1,2-diol Chemical compound N1=C(N)C(OC)=NC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCCC(O)CO)=C1 YJQOTPHRPJQSLQ-FQNRMIAFSA-N 0.000 claims 1
- QGNOTWMPRVBVFZ-FBMWCMRBSA-N 4-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxybutane-1,2-diol Chemical compound COC1=CN=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCCC(O)CO)=N1 QGNOTWMPRVBVFZ-FBMWCMRBSA-N 0.000 claims 1
- RTIMCVAWDIGQHH-LJQANCHMSA-N 4-[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxybutan-1-ol Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCCCCO)=N1 RTIMCVAWDIGQHH-LJQANCHMSA-N 0.000 claims 1
- AEOIOPGFKIUHME-TYJDENFWSA-N 4-[[(7s)-2-amino-7-[2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl]-8,8-difluoro-4-methyl-7h-pyrido[4,3-d]pyrimidin-5-yl]amino]oxybutane-1,2-diol Chemical compound N1=C(N)C(OC)=NC(C=2C(=CC=C(F)C=2)[C@H]2C(C3=NC(N)=NC(C)=C3C(=N/OCCC(O)CO)/N2)(F)F)=C1 AEOIOPGFKIUHME-TYJDENFWSA-N 0.000 claims 1
- ZWSDBPUELLQSJZ-WQHGFJKVSA-N 4-[[(7s)-2-amino-7-[2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl]-8-fluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxybutane-1,2-diol Chemical compound N1=C(N)C(OC)=NC(C=2C(=CC=C(F)C=2)[C@H]2C(C3=NC(N)=NC(C)=C3C(=N/OCCC(O)CO)/N2)F)=C1 ZWSDBPUELLQSJZ-WQHGFJKVSA-N 0.000 claims 1
- UUMCAVHRUOVLEN-QPDBELLOSA-N 4-[[(7s)-2-amino-8-fluoro-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxybutane-1,2-diol Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@H]2C(C3=NC(N)=NC(C)=C3C(=N/OCCC(O)CO)/N2)F)=N1 UUMCAVHRUOVLEN-QPDBELLOSA-N 0.000 claims 1
- MGITXHIKJISZGA-IHTASXDUSA-N 5-[[[(7r)-2-amino-7-[2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxymethyl]-3,4-dihydroxyoxolan-2-one Chemical compound N1=C(N)C(OC)=NC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC2C(C(O)C(=O)O2)O)=C1 MGITXHIKJISZGA-IHTASXDUSA-N 0.000 claims 1
- IUJOVWRTZOKKAK-JLGDOQARSA-N 5-[[[(7r)-2-amino-7-[4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5-yl]amino]oxymethyl]-3,4-dihydroxyoxolan-2-one Chemical compound COC1=CN=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(/C3=C(C)N=C(N)N=C3C2)=N\OCC2C(C(O)C(=O)O2)O)=N1 IUJOVWRTZOKKAK-JLGDOQARSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XLXNSEBFJITLOU-UHFFFAOYSA-N OCC(CCON=C1C=NC=NC1)O Chemical compound OCC(CCON=C1C=NC=NC1)O XLXNSEBFJITLOU-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- VGPBPWRBXBKGRE-UHFFFAOYSA-N n-(oxomethylidene)hydroxylamine Chemical compound ON=C=O VGPBPWRBXBKGRE-UHFFFAOYSA-N 0.000 claims 1
- 125000005188 oxoalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- AKCMCFPQVUTWFW-UHFFFAOYSA-N pyrrolidin-3-yl acetate Chemical compound CC(=O)OC1CCNC1 AKCMCFPQVUTWFW-UHFFFAOYSA-N 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2572508P | 2008-02-01 | 2008-02-01 | |
| US61/025,725 | 2008-02-01 | ||
| US10159508P | 2008-09-30 | 2008-09-30 | |
| US61/101,595 | 2008-09-30 | ||
| PCT/US2009/032728 WO2009097578A1 (en) | 2008-02-01 | 2009-01-30 | Oxim derivatives as hsp90 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011511003A JP2011511003A (ja) | 2011-04-07 |
| JP2011511003A5 true JP2011511003A5 (enExample) | 2012-03-15 |
| JP5524084B2 JP5524084B2 (ja) | 2014-06-18 |
Family
ID=40436400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545233A Expired - Fee Related JP5524084B2 (ja) | 2008-02-01 | 2009-01-30 | Ｈｓｐ９０阻害剤としてのオキシム誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20110053873A1 (enExample) |
| EP (1) | EP2252595B1 (enExample) |
| JP (1) | JP5524084B2 (enExample) |
| KR (1) | KR20100116206A (enExample) |
| CN (1) | CN101983191B (enExample) |
| AR (1) | AR071452A1 (enExample) |
| AU (1) | AU2009208947B2 (enExample) |
| BR (1) | BRPI0906598A2 (enExample) |
| CA (1) | CA2713658C (enExample) |
| CL (1) | CL2009000228A1 (enExample) |
| CR (1) | CR11659A (enExample) |
| DO (1) | DOP2010000236A (enExample) |
| EA (1) | EA019156B1 (enExample) |
| EC (1) | ECSP10010434A (enExample) |
| ES (1) | ES2475206T3 (enExample) |
| GE (1) | GEP20125718B (enExample) |
| IL (1) | IL207227A0 (enExample) |
| MA (1) | MA32104B1 (enExample) |
| MX (1) | MX2010008269A (enExample) |
| MY (1) | MY150596A (enExample) |
| NZ (1) | NZ587207A (enExample) |
| PE (1) | PE20091371A1 (enExample) |
| SG (1) | SG187502A1 (enExample) |
| TW (1) | TW200946531A (enExample) |
| WO (1) | WO2009097578A1 (enExample) |
| ZA (1) | ZA201005435B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| PE20090110A1 (es) | 2007-03-01 | 2009-04-04 | Chugai Pharmaceutical Co Ltd | Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| GB2449293A (en) * | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| WO2009097578A1 (en) * | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| ITTO20111013A1 (it) | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
| US20130210785A1 (en) | 2012-02-15 | 2013-08-15 | Emory University | Progesterone analogs and uses related thereto |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| WO2014107655A1 (en) * | 2013-01-07 | 2014-07-10 | St. Jude Children's Research Hospital | Use of small molecule unfolder protein response modulators to treat tumors with active sonic hedgehog (ssh) signaling due to smoothened (smo) mutation |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| WO2015023593A1 (en) | 2013-08-12 | 2015-02-19 | Emory University | Progesterone phosphate analogs and uses related thereto |
| EP3194975A4 (en) | 2014-09-17 | 2018-05-02 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
| US9868738B2 (en) | 2014-09-19 | 2018-01-16 | Merck Sharp & Dohme Corp. | Diazine-fused amidines as BACE inhibitors, compositions, and their use |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2018200534A1 (en) * | 2017-04-24 | 2018-11-01 | Samus Therapeutics, Inc. | Hsp90 inhibitor oral formulations and related methods |
| EP3630291B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| EP4324460A3 (en) | 2017-09-15 | 2024-04-24 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| US20190134219A1 (en) * | 2017-09-15 | 2019-05-09 | Ampersand Biopharmaceuticals, Inc. | Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases |
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| MX2025007723A (es) | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CN112568223B (zh) * | 2020-04-13 | 2023-04-21 | 辽宁先达农业科学有限公司 | 除草组合物及其应用和除草剂 |
| CN111671749A (zh) * | 2020-06-12 | 2020-09-18 | 重庆医科大学 | 双香豆素在制备HBx蛋白稳定性抑制剂中的用途 |
| CN112661668B (zh) * | 2020-12-31 | 2023-07-28 | 辽宁先达农业科学有限公司 | 一种n-取代酰胺类化合物及其制备方法 |
| CN114259564B (zh) * | 2021-11-30 | 2023-03-14 | 清华大学 | Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用 |
| CN115073458A (zh) * | 2022-07-04 | 2022-09-20 | 山东致泰医药技术有限公司 | 一种阿维巴坦钠的制备方法 |
| CN115381816A (zh) * | 2022-08-04 | 2022-11-25 | 武汉市金银潭医院(武汉市传染病医院) | Ver50589在制备抗肠道病毒71型药物中的应用 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117907491B (zh) * | 2024-03-12 | 2024-06-04 | 中国人民解放军军事科学院军事医学研究院 | 基于双衍生化技术的脱碱基位点lc-ms/ms分析方法 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA762455A (en) | 1962-03-22 | 1967-07-04 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Pyrido-pyrimidines |
| DE1197466B (de) | 1962-03-22 | 1965-07-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen |
| GB8912336D0 (en) | 1989-05-30 | 1989-07-12 | Smithkline Beckman Intercredit | Compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| EP1267876A1 (en) * | 2000-03-23 | 2003-01-02 | Merck & Co., Inc. | Thrombin inhibitors |
| WO2001070269A1 (en) | 2000-03-24 | 2001-09-27 | Akzo Nobel N.V. | Keratinocyte growth inhibitors and hydroxamic acid derivatives |
| US6946456B2 (en) | 2000-07-28 | 2005-09-20 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| JPWO2002015925A1 (ja) | 2000-08-22 | 2004-07-08 | 協和醗酵工業株式会社 | アポトーシスの制御方法およびアポトーシス制御ポリペプチド |
| US7439359B2 (en) * | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| CA2440809A1 (en) | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| KR20020089883A (ko) | 2001-05-25 | 2002-11-30 | 주식회사 지인텍 | 마사지 장치 |
| EE200400042A (et) * | 2001-06-28 | 2004-10-15 | Essential Therapeutics, Inc. | 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena |
| JP2005139066A (ja) * | 2001-12-14 | 2005-06-02 | Hsp Research Institute Inc | ２、３−ジヒドロ−１ｈ−キノリン−４−オンオキシム誘導体および熱ショック蛋白質発現誘導阻害剤 |
| JPWO2003068776A1 (ja) | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| AU2003282512A1 (en) | 2002-10-22 | 2004-05-13 | The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Methods of reducing the activity of and reducing the concentration of a mutant kit protein |
| EP1457499A1 (en) | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| US20050020534A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| JPWO2005018674A1 (ja) | 2003-08-22 | 2006-10-19 | 協和醗酵工業株式会社 | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 |
| ATE433974T1 (de) | 2003-09-19 | 2009-07-15 | Gilead Sciences Inc | Azachinolinolphosphonatverbindungen als integraseinhibitoren |
| WO2005070929A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| DE102004041163A1 (de) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| WO2006050333A2 (en) | 2004-11-02 | 2006-05-11 | The Regents Of The University Of California | Methods and compositions for modulating apoptosis |
| BRPI0517268A (pt) | 2004-11-02 | 2008-10-07 | Conforma Therapeutics Corp | método para tratar uma forma de leucemia linfocìtica crÈnica |
| US20080193932A1 (en) | 2004-11-05 | 2008-08-14 | University Of Rochester | Methods Of Inhibiting the Activity of Hsp90 and/or Aryl Hydrocarbon Receptor |
| WO2006078891A2 (en) | 2005-01-21 | 2006-07-27 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
| WO2006083979A2 (en) | 2005-02-02 | 2006-08-10 | Nexgenix Pharmaceuticals, L.L.C. | Local treatment of neurofibromas |
| EP1865775A1 (en) | 2005-04-06 | 2007-12-19 | Irm, Llc | Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors |
| US20070027150A1 (en) * | 2005-04-14 | 2007-02-01 | Bellamacina Cornelia R | 2-Amino-quinazolin-5-ones |
| JP5198256B2 (ja) | 2005-05-04 | 2013-05-15 | エボテク エージー | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
| WO2006124904A2 (en) | 2005-05-16 | 2006-11-23 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and hsp90 activities |
| US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
| US20070105874A1 (en) | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| US7851468B2 (en) | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| EP2019677B1 (en) | 2006-05-16 | 2013-08-14 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| WO2007143629A1 (en) | 2006-06-02 | 2007-12-13 | Nexgenix Pharmaceuticals | Treatment of neurofibromatosis with inhibitors of a signal transduction pathway |
| JP5415942B2 (ja) | 2006-06-22 | 2014-02-12 | プラナ バイオテクノロジー リミティッド | 処置の方法およびその処置に有用な薬剤 |
| US20080160520A1 (en) * | 2006-06-22 | 2008-07-03 | Angelika Amon | Methods and Composition for Diagnosing and Treating Cancer |
| WO2008021981A2 (en) | 2006-08-09 | 2008-02-21 | Nexgenix Pharmaceuticals, Llc. | Local treatment of epidermal and dermal hyperproliferative lesions |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| AU2007319209B2 (en) | 2006-11-15 | 2012-04-19 | Genentech, Inc. | Arylsulfonamide compounds |
| WO2008116216A1 (en) | 2007-03-22 | 2008-09-25 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for inhibiting cancer metastasis |
| GB2449293A (en) * | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| WO2009097578A1 (en) * | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
-
2009
- 2009-01-30 WO PCT/US2009/032728 patent/WO2009097578A1/en not_active Ceased
- 2009-01-30 JP JP2010545233A patent/JP5524084B2/ja not_active Expired - Fee Related
- 2009-01-30 NZ NZ587207A patent/NZ587207A/en not_active IP Right Cessation
- 2009-01-30 KR KR1020107019568A patent/KR20100116206A/ko not_active Abandoned
- 2009-01-30 US US12/865,713 patent/US20110053873A1/en not_active Abandoned
- 2009-01-30 CN CN2009801117170A patent/CN101983191B/zh not_active Expired - Fee Related
- 2009-01-30 CA CA2713658A patent/CA2713658C/en not_active Expired - Fee Related
- 2009-01-30 MX MX2010008269A patent/MX2010008269A/es active IP Right Grant
- 2009-01-30 GE GEAP200911937A patent/GEP20125718B/en unknown
- 2009-01-30 ES ES09706850.6T patent/ES2475206T3/es active Active
- 2009-01-30 AU AU2009208947A patent/AU2009208947B2/en not_active Expired - Fee Related
- 2009-01-30 EA EA201070912A patent/EA019156B1/ru not_active IP Right Cessation
- 2009-01-30 BR BRPI0906598-9A patent/BRPI0906598A2/pt not_active IP Right Cessation
- 2009-01-30 SG SG2013004676A patent/SG187502A1/en unknown
- 2009-01-30 EP EP09706850.6A patent/EP2252595B1/en active Active
- 2009-01-30 MY MYPI20103648 patent/MY150596A/en unknown
- 2009-01-30 US US12/363,640 patent/US8071766B2/en not_active Expired - Fee Related
- 2009-02-02 CL CL2009000228A patent/CL2009000228A1/es unknown
- 2009-02-02 AR ARP090100342A patent/AR071452A1/es not_active Application Discontinuation
- 2009-02-02 PE PE2009000150A patent/PE20091371A1/es not_active Application Discontinuation
- 2009-02-02 TW TW098103333A patent/TW200946531A/zh unknown
-
2010
- 2010-07-26 IL IL207227A patent/IL207227A0/en unknown
- 2010-07-29 ZA ZA2010/05435A patent/ZA201005435B/en unknown
- 2010-07-30 DO DO2010000236A patent/DOP2010000236A/es unknown
- 2010-08-26 MA MA33117A patent/MA32104B1/fr unknown
- 2010-08-30 EC EC2010010434A patent/ECSP10010434A/es unknown
- 2010-08-30 CR CR11659A patent/CR11659A/es not_active Application Discontinuation
-
2011
- 2011-10-11 US US13/271,134 patent/US8618290B2/en not_active Expired - Fee Related
-
2012
- 2012-03-01 US US13/410,045 patent/US20120172321A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2608940T3 (es) | Derivado de bicicloanilina | |
| JP2022542396A5 (enExample) | ||
| JP6523251B2 (ja) | Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途 | |
| KR100883289B1 (ko) | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 | |
| EP2214669B1 (en) | Cytokine inhibitors | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| CA2623982A1 (en) | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists | |
| WO2019043610A1 (en) | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES | |
| JP5524084B2 (ja) | Ｈｓｐ９０阻害剤としてのオキシム誘導体 | |
| KR20080002963A (ko) | Ｄｎａ－ｐｋ 억제제 | |
| JP2013522286A5 (enExample) | ||
| JP2007521287A5 (enExample) | ||
| SK5402003A3 (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | |
| RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| JP2008523145A5 (enExample) | ||
| CA2969090A1 (en) | Triazolopyrimidine compounds and uses thereof | |
| AU2003215821A1 (en) | Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof | |
| JP2023539985A5 (enExample) | ||
| DK3164393T3 (en) | Flavagline derivatives | |
| JP2015523981A (ja) | テトラヒドロピラゾロピリミジン化合物 | |
| HRP20200564T1 (hr) | 1h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina | |
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
| CA2774731A1 (en) | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | |
| JP7840580B2 (ja) | Ｈｐｋ１阻害剤としての３－［（１ｈ－ピラゾール－４－イル）オキシ］ピラジン－２－アミン化合物及びその使用 | |
| ES2268154T3 (es) | 6,7-dihidro-5h-pirazolo (1,2-a) pirazol-1-onas espirociclicas que controlan citoquinas inflamatorias. |